Edesa Biotech is a clinical-stage private company focused on developing treatments for dermatological and anorectal diseases. Their initial focus is on developing novel, safe and potent alternatives to steroids for allergic contact dermatitis, hemorrhoids, and anal fissures. Edesa Biotech's lead asset, EB01 is a novel non-steroidal anti-inflammatory molecule for the treatment of allergic contact dermatitis which has already demonstrated statistically significant improvements in multiple clinical studies.
As of April 2020, Edesa Biotech's clinical pipeline includes their EB01 topical treatment for contact dermatitis which was in Phase 2 of clinical trials; their EB01 topical treatment for hemorrhoids which was in Phase 1 of clinical trials; their EB04 topical treatment for anal fissures which was in Phase 1 of clinical trials; their EB05 and EB06 acute respiratory distress syndrome mAb treatment which were both in Phase 2 of clinical trials; and their immunotherapy for vitiligo which was heading into lead optimization as of April, 2020.
In May 2019, Stellar Biotechnologies shareholders approved a reverse merger with Edesa Biotech, in which the privately owned Edesa Biotech was brought onto the public market under Stellar Biotechnologies shares on the NASDAQ. As per the terms of the agreement, Edesa Biotech shareholders exchanged their shares for newly issued shares of Stellar. Edesa Biotech shareholders would own 90% of the new company. The new company retains Edesa Biotech's name, but the company has become a wholly owned subsidiary of Stellar Biotechnologies.
Blair Gordon, PhD
Vice President, Research and Development
Vice President, Investor Relations and Communications
Kathi Niffenegger, CPA
Chief Financial Officer
Michael Brooks, PhD, MBA
Par Nijhawan, MD, FRCPC, AGAF
Chief Executive Officer